2013
Tyrosine-kinase inhibitors in oncology
Tsao A, Papadimitrakopoulou V, Herbst R. Tyrosine-kinase inhibitors in oncology. 2013, 872-883. DOI: 10.1017/cbo9781139046947.083.Peer-Reviewed Original ResearchHigh-throughput technologiesKey oncogenic pathwaysGenomic eraMechanistic targetComplexity of cancerOncogenic pathwaysMolecular perspectiveHuman cancersMolecular oncologyMolecular changesHuman malignanciesPathwayCancer tissuesCritical driverTyrosine kinase inhibitorsMalignant transformationNew discoveriesGenomicsDiscoveryGenesMutationsEnormous stridesNew drugsInhibitorsCancer
1991
Differential regulation of hepatocyte-enriched transcription factors explains changes in albumin and transthyretin gene expression among hepatoma cells.
Herbst RS, Nielsch U, Sladek F, Lai E, Babiss LE, Darnell JE. Differential regulation of hepatocyte-enriched transcription factors explains changes in albumin and transthyretin gene expression among hepatoma cells. The New Biologist 1991, 3: 289-96. PMID: 1878351.Peer-Reviewed Original ResearchMeSH KeywordsAlbuminsAnimalsBase SequenceCCAAT-Enhancer-Binding ProteinsDNADNA-Binding ProteinsGene Expression RegulationHepatocyte Nuclear Factor 1Hepatocyte Nuclear Factor 1-alphaHepatocyte Nuclear Factor 1-betaHepatocyte Nuclear Factor 3-alphaHepatocyte Nuclear Factor 3-betaHepatocyte Nuclear Factor 3-gammaHepatocyte Nuclear Factor 4LiverMolecular Sequence DataNuclear ProteinsOligonucleotidesPhosphoproteinsPrealbuminRatsRNA, MessengerTranscription FactorsTumor Cells, CulturedConceptsTranscription factorsHepatocyte-enriched transcription factorsDNA-binding proteinsTransthyretin gene expressionRegulation of genesDNA-binding activityRat hepatoma cell lineLevel of expressionTranscriptional activityGene expressionHepatoma cell lineDifferential regulationCellular concentrationGenesHepatoma cellsCell linesExpressionRegulationTransthyretin geneLFB1HNF4HNF3ProteinEBPDifferent rates